Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2500-2502

  Higgins, Rachel R ^a   Beniprashad, Melissa ^a   Chong King, Eddie ^a   Li, Yan ^e   Bastien, Nathalie ^e   Low, Donald E ^a,b,c   Gubbay, Jonathan B ^a,b,d  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; VIRUS DNA; VIRUS SIALIDASE; ZANAMIVIR;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; CLINICAL FEATURE; DNA SEQUENCE; ENZYME ACTIVE SITE; HUMAN; IC 50; INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MALE; MUTATIONAL ANALYSIS; NA GENE; NONHUMAN; NOSE SMEAR; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; THROAT CULTURE; VIRUS CARRIER; VIRUS CULTURE; VIRUS GENE; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; POINT MUTATION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; ZANAMIVIR;

EID: 84862751937     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00682-12     Document Type: Article

References (18)

1. Abed Y, Baz M, Boivin G. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11:971-976.
2. Baranovich T, et al. 2010. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J. Clin. Virol. 47:23-28.
3. Baum EZ, et al. 2003. A point mutation in influenza B confers resistance to peramivir and loss of slow binding. Antiviral Res. 59:13-22.
4. Collins PJ, et al. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258-1262.
5. Colman PM, Hoyne PA, Lawrence MC. 1993. Sequence structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67:2972-2980.
6. Dharan NJ, et al. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
7. Hatakeyama S, et al. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442.
8. Hurt AC, Holien JK, Barr IG. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:4433-4440.
9. Le QM, et al. 2005. Avian flu: isolation of drug-resistant H5N1. Nature 437:1108. (Erratum, 438:754.)
10. Longtin J, et al. 2011. Neuraminidase-inhibitor resistance testing for pandemic influenza A(H1N1) 2009 in Ontario, Canada. J. Clin. Virol. 50:257-261.
11. Monto AS, et al. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402.
12. Moscona A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956.
13. MRC National Institute for Medical Research, WHO Influenza Centre London. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere, February 2012, September 2011, February 2011, September 2010, and February 2010. Accessed April 2012. http://www.nimr.mrc.ac.uk/who-influenza-centre/annual-and-interim-reports/.
14. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 51:983-984.
15. Okomo-Adhiambo M, et al. 2010. Detection of E119V and E119I mutations in influenza A(H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54:1834-1841.
16. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. 2010. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res. 85:354-360.
17. Sheu TG, et al. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
18. van der Vries E, Stelma FF, Boucher CAB. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363:1381-1382.